
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists are effective in lowering blood sugar by stimulating insulin release and reducing glucose production in the liver. These medications are commonly prescribed when oral diabetes drugs like metformin are insufficient for controlling blood sugar levels. Some GLP-1 agonists have also been shown to reduce the risk of heart-related events in people with type 2 diabetes and existing heart disease.
For individuals without diabetes, GLP-1 agonists like Wegovy and Saxenda are FDA-approved for weight loss. By enhancing feelings of fullness and reducing appetite, these drugs make it easier for individuals to eat less without experiencing hunger. Clinical studies have shown that combining GLP-1 therapy with lifestyle changes leads to significant and lasting weight loss for many patients.
GLP-1 receptor agonists regulate blood sugar by enhancing insulin secretion after meals and reducing glucagon production. This dual mechanism helps prevent sharp increases in blood glucose and ensures better overall glycemic control. Because the response is glucose-dependent, the risk of hypoglycemia (low blood sugar) is significantly lower compared to many traditional diabetes medications.
A key benefit of GLP-1 therapy is its ability to support long-term weight loss and weight management. By slowing gastric emptying and signaling the brain to increase feelings of fullness, GLP-1 medications help reduce hunger, making it easier for individuals to consume fewer calories. Clinical studies show that medications like liraglutide, semaglutide, and tirzepatide lead to significant and sustained weight loss when combined with lifestyle changes.



GLP-1/GIP co-agonists activate both GLP-1 and GIP receptors, improving insulin secretion and appetite control more effectively than GLP-1 alone. These dual-action drugs offer a more powerful approach to managing blood sugar and hunger, making them a promising option for treating diabetes and obesity.
GLP-1/glucagon co-agonists target both GLP-1 and glucagon receptors to improve weight loss and energy metabolism while preserving lean muscle mass.

